Program
UA026
A development code.
Its studies are mostly in Psoriasis, led by Usynova Pharmaceuticals.
Furthest: phase 1, since Jun 8, 20251 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Usynova Pharmaceuticals | 11 open or running | phase 1since Jun 8, 2025 | Jun 8, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 8, 2025First study: phase 1 study in Plaque PsoriasisFirst studyNCT07038720 · 124 planned · China
TargetBeta
IL17A →read by rule
“Inhibiting IL-17A has shown remarkable clinical efficacy in psoriasis.UA026 is a high potency small molecule IL-17A inhibitor.”study text, by rule · the study
Other programs on IL17A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| secukinumabrule | Novartis | phase 4 | 128 |
| ixekizumabrule | Eli Lilly | phase 4 | 38 |
| vunakizumabrule | Jiangsu HengRui Medicine | phase 4 | 17 |
| bimekizumabrule | UCB | phase 3 | 43 |
| sonelokimabrule | moonlake-immunotherapeutics-ag | phase 3 | 12 |
| tibulizumabrule | Eli Lilly | phase 2 | 5 |
| SCT650Crule | Sinocelltech Group | phase 2 | 3 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07038720Plaque Psoriasis · China | 1 | Recruiting | Mar 1, 2026 | 124 |
How it is read
Names in the registry
- “UA026”, 1 entry
Codes read as this program: UA026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.